164 related articles for article (PubMed ID: 36537978)
1. Facioscapulohumeral Muscular Dystrophy.
Mul K
Continuum (Minneap Minn); 2022 Dec; 28(6):1735-1751. PubMed ID: 36537978
[TBL] [Abstract][Full Text] [Related]
2. Facioscapulohumeral Muscular Dystrophies.
Wagner KR
Continuum (Minneap Minn); 2019 Dec; 25(6):1662-1681. PubMed ID: 31794465
[TBL] [Abstract][Full Text] [Related]
3. Facioscapulohumeral muscular dystrophy: the road to targeted therapies.
Tihaya MS; Mul K; Balog J; de Greef JC; Tapscott SJ; Tawil R; Statland JM; van der Maarel SM
Nat Rev Neurol; 2023 Feb; 19(2):91-108. PubMed ID: 36627512
[TBL] [Abstract][Full Text] [Related]
4. DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Bittel A; Maruyama R; Echigoya Y; Nguyen Q; Huang Y; Dzierlega K; Zhang A; Chen YW; Yokota T
Mol Ther; 2021 Feb; 29(2):848-858. PubMed ID: 33068777
[TBL] [Abstract][Full Text] [Related]
5. Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.
Campbell AE; Belleville AE; Resnick R; Shadle SC; Tapscott SJ
Hum Mol Genet; 2018 Aug; 27(R2):R153-R162. PubMed ID: 29718206
[TBL] [Abstract][Full Text] [Related]
6. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
[TBL] [Abstract][Full Text] [Related]
7. Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy.
Himeda CL; Jones TI; Virbasius CM; Zhu LJ; Green MR; Jones PL
Mol Ther; 2018 Jul; 26(7):1797-1807. PubMed ID: 29759937
[TBL] [Abstract][Full Text] [Related]
8. Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings.
Jia FF; Drew AP; Nicholson GA; Corbett A; Kumar KR
Neuromuscul Disord; 2021 Nov; 31(11):1101-1112. PubMed ID: 34711481
[TBL] [Abstract][Full Text] [Related]
9. Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics.
Chen JC; King OD; Zhang Y; Clayton NP; Spencer C; Wentworth BM; Emerson CP; Wagner KR
Mol Ther; 2016 Aug; 24(8):1405-11. PubMed ID: 27378237
[TBL] [Abstract][Full Text] [Related]
10. Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials.
Ghasemi M; Emerson CP; Hayward LJ
Cells; 2022 Feb; 11(4):. PubMed ID: 35203336
[TBL] [Abstract][Full Text] [Related]
11. Knocking Down DUX4 in Immortalized Facioscapulohumeral Muscular Dystrophy Patient-Derived Muscle Cells.
Lim KRQ; Yokota T
Methods Mol Biol; 2023; 2587():197-208. PubMed ID: 36401032
[TBL] [Abstract][Full Text] [Related]
12. Facioscapulohumeral Muscular Dystrophy.
DeSimone AM; Pakula A; Lek A; Emerson CP
Compr Physiol; 2017 Sep; 7(4):1229-1279. PubMed ID: 28915324
[TBL] [Abstract][Full Text] [Related]
13. Transgenic zebrafish model of DUX4 misexpression reveals a developmental role in FSHD pathogenesis.
Pakula A; Lek A; Widrick J; Mitsuhashi H; Bugda Gwilt KM; Gupta VA; Rahimov F; Criscione J; Zhang Y; Gibbs D; Murphy Q; Manglik A; Mead L; Kunkel L
Hum Mol Genet; 2019 Jan; 28(2):320-331. PubMed ID: 30307508
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy.
Cohen J; DeSimone A; Lek M; Lek A
Trends Mol Med; 2021 Feb; 27(2):123-137. PubMed ID: 33092966
[TBL] [Abstract][Full Text] [Related]
15. Integrating clinical and genetic observations in facioscapulohumeral muscular dystrophy.
Mul K; van den Boogaard ML; van der Maarel SM; van Engelen BG
Curr Opin Neurol; 2016 Oct; 29(5):606-13. PubMed ID: 27389814
[TBL] [Abstract][Full Text] [Related]
16. Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update.
Schätzl T; Kaiser L; Deigner HP
Orphanet J Rare Dis; 2021 Mar; 16(1):129. PubMed ID: 33712050
[TBL] [Abstract][Full Text] [Related]
17. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
[TBL] [Abstract][Full Text] [Related]
18. Proteomics of Muscle Microdialysates Identifies Potential Circulating Biomarkers in Facioscapulohumeral Muscular Dystrophy.
Corasolla Carregari V; Monforte M; Di Maio G; Pieroni L; Urbani A; Ricci E; Tasca G
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396627
[TBL] [Abstract][Full Text] [Related]
19. Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models.
Nunes AM; Ramirez M; Jones TI; Jones PL
Dis Model Mech; 2021 Aug; 14(8):. PubMed ID: 34338285
[TBL] [Abstract][Full Text] [Related]
20. RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy.
Wallace LM; Liu J; Domire JS; Garwick-Coppens SE; Guckes SM; Mendell JR; Flanigan KM; Harper SQ
Mol Ther; 2012 Jul; 20(7):1417-23. PubMed ID: 22508491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
